Innovation Partnership vs Competitive Procedure with Negotiation in Denmark, Which to Use for Welfare‑tech & R&D Procurements

Danish municipalities and regions running welfare technology procurement face a pivotal procedural choice: launch an Innovation Partnership that bundles R&D co‑development with the later purchase of the resulting solution, or run a Competitive Procedure with Negotiation (CPN) that keeps multiple suppliers competing while you refine technical and financial terms before award. The decision between Innovation Partnership vs Competitive Procedure with Negotiation in Denmark shapes your procurement timeline, IP ownership, challenge risk and, ultimately, whether the solution you need actually reaches production. This guide gives procurement officers, project leads and suppliers a dimension‑by‑dimension decision framework grounded in the Danish Public Procurement Act and EU Directive 2014/24/EU, updated for the procedural clarifications that took practical effect from 1 January 2026.

Innovation Partnership in Denmark, What It Is, When It Applies, Who It Suits

An innovation partnership Denmark procedure allows a contracting authority to select one or more partners, negotiate the terms of a joint development project, execute the R&D phases under a binding contract, and then purchase the resulting innovative product or service, all within a single procurement. The legal basis sits in Articles 31 and 49(4) of Directive 2014/24/EU, transposed into the Danish Public Procurement Act (udbudslov). The procedure exists specifically for situations where no solution available on the market can meet the authority’s needs without new development work.

Legal and Procedural Steps

• Publication and selection. The authority publishes a contract notice, sets minimum capacity and innovation‑capability criteria, and shortlists candidates through a qualification round.
• Negotiation phase. Shortlisted candidates submit initial tenders. The authority negotiates on all aspects except minimum requirements and award criteria. Negotiations must respect equal treatment and confidentiality.
• Partnership award. The contract is awarded to one or more partners based on best price‑quality ratio, with mandatory emphasis on innovative character.
• Development phases. The contract structures successive R&D stages with intermediate targets and milestone payments. The authority may reduce the number of partners at the end of each phase.
• Purchase of result. If the final deliverable meets pre‑agreed performance levels and cost limits, the authority purchases the solution without a new procurement, the purchase is integral to the partnership contract.

Typical Timeline and Milestones

Innovation partnerships for welfare technology procurement in Denmark typically span 18 to 36 months from contract notice to first purchase, depending on R&D complexity. The development phase alone often accounts for 12 to 24 months. Milestone gates, such as proof‑of‑concept validation, prototype testing in a live care environment, and user‑acceptance review, must be defined in the contract before award.

Practical Welfare‑Tech Example

A Danish municipality needs an automated medication‑dispensing system that integrates with existing electronic health records. No market‑ready product can do this. The municipality selects two innovation partners, funds parallel prototyping, tests both systems in pilot care homes, and retains the partner whose solution passes clinical validation and cost thresholds, purchasing the finished units under the same contract without re‑tendering.

Competitive Procedure with Negotiation in Denmark, What It Is, When It Applies, Who It Suits

The competitive procedure with negotiation Denmark route lets an authority publish a contract notice, receive initial tenders, and then negotiate with shortlisted bidders to improve technical solutions and commercial terms before requesting final offers. It is governed by Article 29 of Directive 2014/24/EU and the corresponding provisions of the Danish Public Procurement Act. Unlike competitive dialogue vs innovation partnership routes, the CPN presupposes that the market can deliver a working solution, the negotiation is about refining, not inventing.

Legal and Procedural Steps

• Publication and qualification. The authority publishes minimum requirements, selection criteria and award criteria. Candidates submit selection materials and initial tenders.
• Shortlisting. The authority reduces the field to a minimum of three candidates (unless fewer qualified candidates applied).
• Negotiation rounds. The authority may conduct successive rounds of negotiation on all aspects of the tenders except minimum requirements and award criteria. After each round, the authority may further narrow the field if it reserved that right in the contract notice.
• Final tender and award. The authority sets a deadline for final offers, evaluates them against the published award criteria, and awards the contract. An automatic standstill period applies before contract signature.

Typical Timeline and Milestones

A well‑managed CPN for a welfare‑tech contract in Denmark typically runs 6 to 12 months from publication to award, depending on the number of negotiation rounds and the complexity of technical specifications. Two to three negotiation rounds are common. Each round adds roughly four to six weeks to the procurement timeline.

Example: Welfare‑Tech Without Co‑Development

A Danish region wants to procure sensor‑based fall‑detection systems for home‑care users. Several commercially available systems exist, but the region needs customised data integration, specific battery‑life requirements, and bespoke service‑level agreements. A CPN lets the region negotiate with three shortlisted suppliers to tailor specifications and pricing, then award to the supplier whose final offer scores highest, all while maintaining competitive pressure throughout.

Innovation Partnership vs Competitive Procedure with Negotiation, A Plain‑Terms Comparison

The table below compares the two procedures across every dimension that matters for a procurement procedure choice in 2026. Read each row as an independent decision criterion: if the Innovation Partnership column describes your project reality, that cell carries the weight for that dimension.

Three takeaways from the table:

• The dividing line is whether a market‑ready solution exists. If no product on the market can meet your need, the Innovation Partnership is the only lawful integrated route. If solutions exist but need refinement, CPN is the more efficient and lower‑risk path.
• IP complexity scales with procedure choice. Innovation partnerships demand bespoke IP and commercialisation clauses from day one; CPN contracts typically rely on standard foreground/background IP provisions.
• Timeline and challenge risk run in opposite directions. Innovation partnerships take longer but embed the purchase; CPN is faster to award but still exposes you to challenge risk if negotiation records are inadequate.

Dimension‑by‑Dimension Analysis

IP & Commercialisation

IP allocation is the single most consequential contractual difference between the two procedures. In an innovation partnership Denmark procurement, the authority co‑funds development and expects to acquire or license the resulting foreground IP. The contract must address background IP contributions, foreground IP ownership or licensing, exploitation rights (including whether the supplier may commercialise the solution to third parties), step‑in rights if the partnership is terminated, confidentiality, and sublicensing. Failure to settle these terms before contract award is the most common source of disputes and post‑award renegotiation.

Under a CPN, IP clauses are simpler. The supplier delivers a product or service it has already developed; the authority receives a licence to use it. Foreground IP, any adaptation or customisation, is typically assigned to the authority or jointly owned, depending on the contract. Commercialisation risk is low because the supplier retains its existing product IP.

Timing & Project Delivery

Innovation partnerships carry inherent schedule risk because the deliverable does not yet exist. Milestone gating, where the authority reviews R&D outputs against pre‑defined criteria before funding the next phase, is the primary control tool. If no partner passes a gate, the authority may terminate the partnership and, in practice, must restart procurement from scratch.

• Innovation Partnership: 18–36 months typical; R&D phases dominate the timeline; schedule overruns are common in welfare‑tech pilots involving clinical testing or regulatory approvals.
• CPN: 6–12 months typical; each negotiation round adds 4–6 weeks; timeline is more predictable because the product concept already exists.

Competition & Number of Suppliers

Maintaining competition is a legal requirement under both procedures, but the dynamics differ sharply. In an innovation partnership, the authority may start with multiple development partners but is permitted to reduce to a single partner at each milestone gate, provided this possibility was stated in the contract notice. Early indications from Danish practice suggest that retaining at least two partners through the development phase significantly reduces both unit cost and challenge risk.

• Innovation Partnership: Start with 2–3 partners; structured reduction to 1 is permissible but must be documented and justified at each gate.
• CPN: Minimum three candidates invited to negotiate (unless fewer qualified); competitive tension maintained through to final offer submission.

Documentation & Justification

Both procedures require comprehensive procurement files, but the justification burden differs in kind. For an innovation partnership, the file must demonstrate that no existing market solution can satisfy the authority’s need, this is the threshold test. The authority must also record every negotiation session, milestone decision and partner‑reduction rationale. For a CPN, the primary documentation duty is to show that each negotiation round treated all bidders equally and that award criteria were applied consistently.

• Innovation Partnership: Justify the absence of a market solution; document each milestone gate; record IP negotiation outcomes; maintain a full development‑phase audit trail.
• CPN: Document each negotiation round; record substantive changes to tenders; justify any narrowing of the candidate field; maintain equal‑treatment evidence.

Liability & Warranties

R&D failure risk is the defining liability question. In an innovation partnership, the authority shares development risk: if the technology fails at the prototype stage, milestone payments already made are sunk costs. The contract should cap the authority’s total exposure and require the partner to carry professional indemnity and, where relevant, product‑liability insurance. Under a CPN, the supplier bears the product risk, standard warranty and defect‑liability clauses apply because the deliverable is a known quantity.

• Innovation Partnership: Authority shares R&D risk; must negotiate liability caps, indemnities and insurance at contract stage; step‑in rights are essential if a partner defaults mid‑development.
• CPN: Supplier bears product risk; standard warranties, defect‑notification periods and liquidated damages apply.

Risk of Challenge & Remedies

The risk profile tracks the degree of restricted competition. Innovation partnerships face elevated scrutiny because the procedure can result in a direct purchase from a single development partner without re‑tendering. The strongest defences are: robust market analysis proving no existing solution, transparent milestone criteria, and documented equal treatment during the negotiation phase. For a CPN, challenge risk centres on inconsistent treatment of bidders during negotiations, for example, sharing one bidder’s solution concept with another, or changing evaluation criteria mid‑process.

• Innovation Partnership: Primary challenge vector, failure to prove that the market cannot supply the solution. Secondary vector, perceived favouritism during partner reduction.
• CPN: Primary challenge vector, inconsistent negotiation conduct or post‑hoc changes to award criteria. The standstill period under the Danish Complaints Board for Public Procurement applies before contract signing.

What Changes in 2026 for This Procurement Procedure Choice

The 2025–26 cycle brought three practical shifts that affect the Innovation Partnership vs Competitive Procedure with Negotiation Denmark decision:

• Stronger documentation for Innovation Partnership eligibility. Updated EU Commission guidance and Danish interpretive practice now expect contracting authorities to include a formal market analysis, not merely a narrative assertion, proving that no existing solution meets the identified need. Industry observers expect the Danish Complaints Board to apply this standard more rigorously from 2026.
• Slightly expanded grounds for CPN. Clarified guidance confirms that authorities may use a CPN whenever the nature of the procurement, its complexity or its legal/financial structure means that a contract cannot be awarded without prior negotiation. This broadens the comfort zone for procurement teams that previously defaulted to open procedure for technically complex welfare‑tech contracts.
• Threshold and tender‑design impact. EU procurement thresholds updated for the 2024–2025 cycle continue to apply, and the procedural documentation requirements interact with those thresholds. Authorities below the EU threshold who use Danish light‑regime rules have more flexibility but still face transparency obligations that mirror the full‑regime documentation duties.

The net effect: Innovation Partnerships remain viable but require more upfront investment in market analysis and documentation. CPN becomes the more accessible route for procurements where the authority can demonstrate that negotiation, rather than co‑development, will yield the best outcome.

Decision Framework: When to Choose Innovation Partnership, When to Choose CPN

Choose Innovation Partnership when:

• No product or service on the market can meet your identified need without new R&D work.
• You need the procurement contract itself to fund and govern the development process.
• IP co‑ownership or a commercialisation roadmap is a core project objective.
• You can commit budget and staff to multi‑year milestone management.
• You have completed a formal market analysis and can document the absence of an existing solution.

Choose Competitive Procedure with Negotiation when:

• Existing products or services can meet your need, but specifications, integration requirements or pricing need refinement through dialogue.
• You want to maintain competitive pressure among multiple suppliers through to final award.
• Timeline is a constraint, you need contract award within 6 to 12 months.
• IP issues are limited to standard licensing of the supplier’s existing product and ownership of bespoke adaptations.
• You want to reduce legal challenge risk by avoiding the restricted‑competition perception associated with innovation partnerships.

When to Engage a Lawyer for This Decision

Not every welfare‑tech procurement needs external counsel from day one, but certain triggers should move this decision into professional legal advice immediately:

• Planned IP transfer or commercialisation. If the procurement will generate new IP that either party intends to exploit commercially, the IP and commercialisation clauses require specialist drafting, standard templates are insufficient.
• Multi‑party consortia or cross‑border suppliers. Consortium agreements, joint‑liability structures and cross‑border enforcement raise complexity that exceeds most in‑house procurement teams’ capacity.
• High contract value or threshold proximity. Procurements near or above EU thresholds trigger mandatory full‑regime procedures and stand‑still obligations; mis‑classification creates material challenge risk.
• Material risk of challenge from unsuccessful bidders. If you anticipate a challenge, because the market is concentrated, or your procedure choice is unusual for the contract type, counsel should review the statutory justification memo, draft procurement documents and evaluation model before publication.
• Staged award or milestone‑gated contracts. Innovation Partnership contracts with development phases require bespoke contract architecture (milestone definitions, payment triggers, partner‑reduction clauses, termination provisions). These are not standard form.

A typical engagement scope for this procurement procedure choice covers: review of the statutory justification memo, drafting or review of procurement documents and evaluation criteria, IP and consortium agreements, and staged award contract templates. Expect to budget for a focused legal workstream running parallel to your procurement timetable.

Sources

1. The Public Procurement Act (Denmark), official English PDF
2. EUR‑Lex, Directive 2014/24/EU
3. European Commission, Public Procurement Procedures Explainer
4. SIGMA (OECD/EU), Public Procurement Procedures
5. DTU, Procurement Innovation Case Studies
6. CBS Research, Denmark Procurement Guidance and 2026 Interpretation